The role of sugammadex in the development and modification of an allergic response to rocuronium: Evidence from a cutaneous model

Anaesthesia

Volumn 67, Issue 3, 2012, Pages 266-273

  Clarke, R C ^a,b   Sadleir, P H M ^a   Platt, P R ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b Anaesthetic Allergy Referral Centre of Western Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CYCLODEXTRIN; ROCURONIUM; SANDOZ; SUGAMMADEX; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE SYSTEM;

ANAPHYLAXIS; ANDROSTANOLS; DRUG HYPERSENSITIVITY; GAMMA-CYCLODEXTRINS; HUMANS; IMMUNOGLOBULIN E; NEUROMUSCULAR NONDEPOLARIZING AGENTS; OFF-LABEL USE; SKIN TESTS;

EID: 84856923054     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2011.06995.x     Document Type: Article

References (24)

1. Hepner DL, Castells MC,. Anaphylaxis during the perioperative period. Anesthesia and Analgesia 2003; 97: 1381-95. (Pubitemid 37310138)
2. Mertes PM, Aimone-Gastin I, Guéant-Rodriguez RM, et al., Hypersensitivity reactions to neuromuscular blocking agents. Current Pharmaceutical Design 2008; 14: 2809-25.
3. Soar J, Pumphrey R, Cant A, et al., Emergency treatment of anaphylactic reactions-guidelines for healthcare providers. Resuscitation 2008; 77: 157-69.
4. Paolini R, Jouvin MH, Kinet JP,. Phosphorylation and dephosphorylation of the high-affinity receptor for immunoglobulin E immediately after receptor engagement and disengagement. Nature 1991; 353: 855-8. (Pubitemid 21912641)
5. Naguib M,. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia and Analgesia 2007; 104: 575-84.
6. Sparr HJ, Vermeyen KM, Beaufort AM, et al., Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety and pharmacokinetics. Anesthesiology 2007; 106: 935-43. (Pubitemid 46684059)
7. Ploeger BA, Smeets J, Strougo A, et al., Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009; 110: 95-105.
8. De Haes A, Proost JH, Kuks JB, van den Tol DC, Wierda JM,. Pharmacokinetic/pharmacodynamic modeling of rocuronium in myasthenic patients is improved by taking into account the number of unbound acetylcholine receptors. Anesthesia and Analgesia 2002; 95: 588-96. (Pubitemid 35006848)
9. Booij LH,. Neuromuscular transmission and its pharmacological blockade. Part 1: Neuromuscular transmission and general aspects of its blockade. Pharmacy World and Science 1997; 19: 1-12. (Pubitemid 27135243)
10. Jones PM, Turkstra TP,. Mitigation of rocuronium-induced anaphylaxis by sugammadex: the great unknown. Anaesthesia 2010; 65: 89-90.
11. McDonnell NJ, Pavy TJ, Green LK, Platt PR,. Sugammadex in the management of rocuronium-induced anaphylaxis. British Journal of Anaesthesia 2011; 106: 199-201.
12. Pedersen NA, Findsen L, Olsen KS,. Should sugammadex be used for the treatment of anaphylaxis induced by rocuronium? Proceedings of the 2010 Annual Meeting of the American Society of Anesthesiologists, 2010. (accessed 28/11/2011).
13. Funnell AE, Griffiths J, Hodzovic I,. A second case of rocuronium-induced anaphylaxis treated with sugammadex. British Journal of Anaesthesia E-Letter 2011. (accessed 21/06/2011).
14. Harper NJN,. Mitigation of rocuronium-induced anaphylaxis by sugammadex: a great unknown. Anaesthesia 2010; 65: 90.
15. Golden DB,. What is anaphylaxis? Current Opinion in Allergy and Clinical Immunology 2007; 7: 331-6. (Pubitemid 47052021)
16. Ogawa Y, Grant JA,. Mediators of anaphylaxis. Immunology and Allergy Clinics of North America 2007; 27: 249-60. (Pubitemid 46705479)
17. He S, Walls AF,. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. European Journal of Pharmacology 1997; 328: 89-97. (Pubitemid 27241401)
18. Peavy RD, Metcalfe DD,. Understanding the mechanisms of anaphylaxis. Current Opinion in Allergy and Clinical Immunology 2008; 8: 310-5.
19. Brown SGA, Mullins RJ, Gold MS,. Anaphylaxis: diagnosis and management. Medical Journal of Australia 2006; 185: 283-9.
20. MacGlahsan DW Jr,. Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. Journal of Allergy and Clinical Immunology 1993; 91: 605-15.
21. Payne V, Kam PCA,. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004; 59: 695-703. (Pubitemid 38997011)
22. Laxenaire MC, Gastin I, Moneret-Vautrin DA, Widmer S, Guéant JL,. Cross-reactivity of rocuronium with other neuromuscular blocking agents. European Journal of Anaesthesiology 1995; 11: 55-64.
23. Association of Anaesthetists of Great Britain and Ireland. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 2009; 64: 199-211.
24. Leysen J, Bridts CH, De Clerck LS, Ebo DG,. Rocuronium-induced anaphylaxis is probably not mitigated by sugammadex: evidence from an in vitro experiment. Anaesthesia 2011; 66: 526-7.